natgillin/translations-raw huggingface dataset:
Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function [e.g. atypical antipsychotics and phenothiazines, most tricyclic antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid (ASA)] (see section 4.5) and in patients with known bleeding tendencies/disorders.
Savjetuje se oprez u bolesnika koji uzimaju antikoagulanse i/ili lijekove za koje je poznato da utječu na funkciju trombocita [npr. atipični antipsihotici i fenotiazini, većina tricikličkih antidepresiva, nesteroidni protuupalni lijekovi (NSAIL-i)), acetilsalicilna kiselina (ASK)] (vidjeti dio 4.5) te u bolesnika s poznatim sklonostima/poremećajima krvarenja.
Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function [e.g., atypical antipsychotics and phenothiazines, most tricyclic antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid (ASA)] (see section 4.5) and in patients with known bleeding tendencies/disorders.
Savjetuje se oprez u bolesnika koji uzimaju antikoagulanse i/ili lijekove za koje je poznato da utječu na funkciju trombocita [npr. atipični antipsihotici i fenotiazini, većina tricikličkih antidepresiva, nesteroidni protuupalni lijekovi (NSAIL-i)), acetilsalicilna kiselina (ASK)] (vidjeti dio 4.5) te u bolesnika s poznatim sklonostima/poremećajima krvarenja.
Caution is advised in the treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly, glucocorticoids, selective serotonin reuptake inhibitors or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.
Savjetuje se oprez u liječenju bolesnika koji su izloženi najvećem riziku od razvoja gastrointestinalnih komplikacija nesteroidnim protuupalnim lijekovima; starijih bolesnika, bolesnika koji istodobno uzimaju druge nesteroidne protuupalne lijekove ili acetilsalicilnu kiselinu, glukokortikoide, selektivne inhibitore ponovne pohrane serotonina ili bolesnika koji su u povijesti bolesti imali gastrointestinalnu bolest, kao što je ulkus ili GI krvarenje.
Caution is advised in the treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly, glucocorticoids, selective serotonin reuptake inhibitors, or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.
Savjetuje se oprez u liječenju bolesnika koji su izloženi najvećem riziku od razvoja gastrointestinalnih komplikacija nesteroidnim protuupalnim lijekovima; starijih bolesnika, bolesnika koji istodobno uzimaju druge nesteroidne protuupalne lijekove ili acetilsalicilnu kiselinu, glukokortikoide, selektivne inhibitore ponovne pohrane serotonina ili bolesnika koji su u povijesti bolesti imali gastrointestinalnu bolest, kao što je ulkus ili GI krvarenje.
Caution is advised when administering Cubicin to patients who already have some degree of renal impairment (creatinine clearance < 80 ml/min) before commencing therapy with Cubicin.
Savjetuje se oprez pri primjeni Cubicina u bolesnika s već prisutnim oštećenjem bubrega određenoga stupnja (klirens kreatinina <80 ml/min) prije početka terapije Cubicinom.
Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop diuretics since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see section 4.4).
Savjetuje se oprez kod primjene bisfosfonata s aminoglikozidima, kalcitoninom ili diureticima Henleove petlje budući da tijekom duljeg razdoblja ti lijekovi mogu imati aditivan učinak i sniziti razinu kalcija u serumu više nego što je potrebno (vidjeti dio 4.4).
Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see section 4.4).
Savjetuje se oprez kod primjene bisfosfonata s aminoglikozidima, kalcitoninom ili diureticima Henleove petlje budući da tijekom duljeg razdoblja ti lijekovi mogu imati aditivan učinak i sniziti razinu kalcija u serumu kroz dulje razdoblje nego što je potrebno (vidjeti dio 4).
Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see section 4.4)..
Savjetuje se oprez kod primjene bisfosfonata s aminoglikozidima, kalcitoninom ili diureticima Henleove petlje budući da tijekom duljeg razdoblja ti lijekovi mogu imati aditivan učinak i sniziti razinu kalcija u serumu više nego što je potrebno (vidjeti dio 4.4).
Caution is advised when bisphosphonates are administered with aminoglycosides, since both agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required.
Savjetuje se oprez kod primjene bisfosfonata s aminoglikozidima, budući da tijekom duljeg razdoblja oba lijeka mogu imati aditivan učinak i sniziti razinu kalcija u serumu više nego što je potrebno.
Caution is advised when co-administering with strong CYP 3A4 inhibitors (e.g. ketoconazole, ritonavir) as there is potential for increased systemic exposure to both fluticasone furoate and vilanterol, and concomitant use should be avoided.
Preporučuje se oprez pri istodobnoj primjeni sa snažnim inhibitorima CYP 3A4 (npr. ketokonazolom, ritonavirom) jer postoji mogućnost povećane sistemske izloženosti i flutikazonfuroatu i vilanterolu pa istodobnu primjenu treba izbjegavati.
Caution is advised when combining stiripentol with other substances that inhibit or induce one or more of these enzymes.
Savjetuje se oprez kad se kombinira stiripentol s drugim tvarima koje inhibiraju ili induciraju jedan ili više ovih enzima.
Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold [e.g., antidepressants (tricyclics, SSRIs, SNRIs), neuroleptics (phenothiazines, thioxanthenes and butyrophenones), mefloquine, bupropion, tramadol] (see section 4.4).
Savjetuje se oprez pri istodobnoj primjeni drugih lijekova koji mogu sniziti prag napadaja [npr. antidepresiva (triciklika, SSRI-a, SNRI-a), neuroleptika (fenotiazina, tioksantena i butirofenona), meflokina, bupropiona, tramadola] (vidjeti dio 4.4).
Caution is advised when Effentora is coadministered with drugs that affect the serotoninergic neurotransmitter systems.
Preporučuje se oprez kod istovremene primjene Effentore i lijekova koji utječu na serotoninergički neurotransmitorski sustav.
Caution is advised when initiating (or changing the dose of) a concomitant systemic substance (irrespective of pharmaceutical form) which may interact with alpha adrenergic receptor agonists or interfere with their activity i.e. agonists or antagonists of the adrenergic receptor e.g. (isoprenaline, prazosin).
Preporučuje se oprez kad se istodobno uvodi (ili se mijenja doza) tvar sa sistemskim učinkom (neovisno o farmaceutskom obliku) koja može međusobno djelovati s agonistima alfa-adrenergičkih receptora ili interferirati s njihovom aktivnošću, odnosno agonisti ili antagonisti adrenergičkih receptora (npr. izoprenalin, prazosin).
Caution is advised when initiating (or changing the dose of) concomitant systemic medicinal products (irrespective of pharmaceutical form) which may interact with α-adrenergic agonists or interfere with their activity i.e. agonists or antagonists of the adrenergic receptor (e.g. isoprenaline, prazosin).
Savjetuje se oprez pri istodobnom uvođenju (ili promjeni doze) sistemskih lijekova (bez obzira na njihov farmaceutski oblik) koji mogu stupati u interakcije s α-adrenergičkim agonistima ili utjecati na njihovu aktivnost, odnosno s agonistima ili antagonistima adrenergičkih receptora (npr. izoprenalin, prazosin).
Caution is advised when Instanyl is coadministered with drugs that affect the serotoninergic neurotransmitter systems.
Preporučuje se oprez kod istovremene primjene Instanyla i lijekova koji utječu na serotoninergički neurotransmitorski sustav.
Caution is advised when leflunomide is given together with drugs, other than NSAIDs, metabolised by CYP2C9 such as phenytoin, warfarin, phenprocoumon and tolbutamide.
Preporučuje se oprez kad se leflunomid daje istodobno s drugim lijekovima, osim nesteroidnih protuupalnih lijekova, koji se metaboliziraju pomoću CYP2C9, poput fenitoina, varfarina, fenprokumona i tolbutamida.
Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the co- administration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5).
Prilikom primjene sildenafila u bolesnika koji uzimaju alfa-blokator savjetuje se oprez jer istodobna primjena može dovesti do simptomatske hipotenzije u manjeg broja osjetljivih osoba (vidjeti dio 4.5).
Caution is advised when SonoVue is administered to patients with clinically significant pulmonary disease, including severe chronic obstructive pulmonary disease.
Savjetuje se oprez kada se SonoVue daje bolesnicima s klinički značajnom plućnom bolesti, uključujući tešku kroničnu opstruktivnu plućnu bolest.
Caution is advised when treating patients ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited (see section 4.4).
Savjetuje se oprez pri liječenju bolesnika u dobi ≥ 65 godina dozama višim od 10 mg vortioksetina jednom dnevno, za koje su podaci ograničeni (vidjeti dio 4.4).
Caution is advised when treating patients ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited (see section 4.4).
Savjetuje se oprez pri liječenju bolesnika u dobi ≥ 65 godina dozama višim od 10 mg vortioksetina jednom dnevno, za koje su podaci ograničeni (vidjeti dio 4.4.).
Caution is advised when TRISENOX is coadministered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine, or medicinal products known to cause hypokalemia or hypomagnesaemia.
Preporučuje se oprez kad se TRISENOX primjenjuje istodobno s drugim lijekovima za koje se zna da uzrokuju produljenje QT/QTc intervala poput makrolidnih antibiotika, antipsihotika tioridazina ili lijekovima za koje se zna da uzrokuju hipokalemiju ili hipomagnezijemiju.
Caution is advised when using medicinal products such as antihypertensives and/or cardiac glycosides concomitantly with SIMBRINZA or in patients with severe or unstable and uncontrolled cardiovascular disease (see section 4.5)
Potreban je oprez pri istodobnoj primjeni SIMBRINZE i lijekova kao što su antihipertenzivi i/ili srčani glikozidi ili kod bolesnika s teškom ili nestabilnom i nekontroliranom kardiovaskularnom bolešću (vidjeti dio 4.5).
Caution is advised when using medicinal products such as antihypertensives and/or cardiac glycosides concomitantly with SIMBRINZA.
Preporuča se oprez pri istodobnoj primjeni lijekova kao što su antihipertenzivi i/ili srčani glikozidi i SIMBRINZE.
Caution is advised when using Onduarp in such patients as amlodipine and telmisartan are not dialysable (see also section 4.4).
Kod takvih bolesnika preporučuje se oprez u primjeni Onduarp, s obzirom da se niti amlodipin niti telmisartan ne uklanjaju dijalizom (također vidjeti dio 4.4).
Caution is advised when using Onduarp in such patients as amlodipine and telmisartan are not dialysable (see also section 4.4).
Kod takvih bolesnika preporučuje se oprez u primjeni Onduarpa, s obzirom da se niti amlodipin niti telmisartan ne uklanjaju dijalizom (također vidjeti dio 4.4).
Caution is advised when using telmisartan/amlodipine in such patients as amlodipine and telmisartan are not dialysable (see also section 4.4).
Kod takvih bolesnika preporučuje se oprez u primjeni kombinacije telmisartan/amlodipin, s obzirom da se niti amlodipin niti telmisartan ne uklanjaju dijalizom (vidjeti također dio 4.4.).
Caution is advised when Zoledronic acid Actavis is administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.
Savjetuje se oprez kada se Zoledronatna kiselina Actavis primjenjuje s antiangiogenim lijekovima, budući da je uočeno povećanje incidencije osteonekroze čeljusti u bolesnika koji se istodobno liječe tim lijekovima.
Caution is advised when Zoledronic Acid Hospira is administered with anti-angiogenic medicinal products as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.
Preporuča se oprez kad se zoledronatna kiselina primjenjuje s antiangiogenim lijekovima jer je primjećena povećana incidencija osteonekroze čeljusti u bolesnika koji su istodobno liječeni ovim lijekovima.
Caution is advised when Zoledronic Acid Hospira is administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.
Preporuča se oprez kad se zoledronatna kiselina primjenjuje s antiangiogenim lijekovima jer je primjećena povećana incidencija osteonekroze čeljusti u bolesnika koji su istodobno liječeni ovim lijekovima.
Caution is advised when zoledronic acid is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5).
Savjetuje se oprez kod primjene Zoledronatna kiselina Mylan s lijekovima za koje je poznato da uzrokuju hipokalcemiju budući da mogu imati sinergistički učinak s posljedičnom teškom hipokalcemijom (vidjeti dio 4.5).
Caution is advised when Zometa is administered with anti-angiogenic medicinal products as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.
Savjetuje se oprez kada se Zometa primjenjuje s antiangiogenim lijekovima, budući da je uočeno povećanje incidencije osteonekroze čeljusti u bolesnika koji se istodobno liječe tim lijekovima.
Caution is also advised if mirabegron is co-administered with CYP2D6 substrates that are individually dose titrated.
Oprez se takoĎer savjetuje pri istodobnoj primjeni mirabegrona sa supstratima CYP2D6 kojima se individualno titrira doza.
Caution is also needed when Stocrin is taken at the same time as other medicines.
Oprez je potreban kada se Stocrin uzima istovremeno s drugim lijekovima.
Caution is also needed when Sustiva is taken at the same time as other medicines.
Oprez je potreban kada se lijek Sustiva uzima istovremeno s drugim lijekovima.
Caution is indicated when zoledronic acid is administered in conjunction with medicinal products that can significantly impact renal function (e.g. aminoglycosides or diuretics that may cause dehydration) (see section 4.4).
Oprez je indiciran kad se zoledronatna kiselina primjenjuje zajedno s lijekovima koji mogu značajno utjecati na bubrežnu funkciju (npr. aminoglikozidi ili diuretici koji mogu uzrokovati dehidraciju) (vidjeti dio 4.4).
Caution is indicated when zoledronic acid is used with other potentially nephrotoxic drugs.
Potreban je oprez kad se zoledronatna kiselina primjenjuje s drugim potencijalno nefrotoksičnim lijekovima.
Caution is indicated when Zoledronic acid Teva is used with other potentially nephrotoxic medicinal products.
Potreban je oprez kad se Zoledronatna kiselina Teva primjenjuje s drugim potencijalno nefrotoksičnim lijekovima.
Caution is needed if Corlentor is taken with some other medicines.
Potreban je oprez ako se Corlentor uzima s određenim drugim lijekovima.
Caution is needed if Ivabradine Anpharm is taken with some other medicines.
Potreban je oprez ako se Ivabradine Anpharm uzima s određenim drugim lijekovima.
Caution is needed if Procoralan is taken with some other medicines.
Potreban je oprez ako se Procoralan uzima s određenim drugim lijekovima.
Caution is needed if you are hypersensitive to tetracycline.
Potreban je oprez ako ste preosjetljivi na tetraciklin.
Caution is needed in elderly patients ≥75 years with multiple co-morbidities (see sections 4.2 and 5.1).
Potreban je oprez u bolesnika u dobi od ≥ 75 godina s višestrukim komorbiditetima (vidjeti dio 4.2 i 5.1).
Caution is needed in patients with coronary artery disease.
Potreban je oprez u bolesnika s bolešću koronarnih arterija.
Caution is needed in patients ≥75 years old when co-morbidities are present (see sections 4.3, 4.4 and 5.1).
Oprez je nužan u bolesnika u dobi od ≥ 75 godina s popratnim bolestima (vidjeti dio 4.3, 4.4 i 5.1).
Caution is needed when administering Revestive to persons with a known hypersensitivity to tetracycline.
Potreban je oprez ako se lijek Revestive primjenjuje osobama s poznatom preosjetljivošću na tetraciklin.
Caution is needed when administering this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients and to trace residues e.g. formaldehyde, benzonase, or sucrose.
Oprez je nužan pri davanju ovog cjepiva osobama s poznatom preosjetljivošću (različitima od anafilaktičke reakcije) na djelatnu tvar, na bilo koju od pomoćnih tvari i na ostatne tvari u tragovima npr. formaldehid, benzonazu ili saharozu.
Caution is needed when administering this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1, to thiomersal and to residues (egg and chicken protein, ovalbumin, formaldehyde and sodium deoxycholate).
Potreban je oprez prilikom primjene ovog cjepiva osobama s poznatom preosjetljivošću (osim anafilaktičke reakcije) na djelatnu tvar, na neku od pomoćnih tvari navedenih u dijelu 6.1, tiomersal i ostatne tvari (jaja i pileći proteini, ovalbumin, formaldehid i natrijev deoksikolat).
Caution is needed when administering this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1, to thiomersal and to residues (egg and chicken protein, ovalbumin, formaldehyde, gentamicin sulphate and sodium deoxycholate).
Potreban je oprez pri primjeni ovog cjepiva u osoba s poznatom preosjetljivošću (pored anafilaktičke reakcije) na djelatnu tvar, neku od pomoćnih tvari navedenih u dijelu 6.1, tiomersal i ostatne tvari (jaja i pileće proteine, ovalbumin, formaldehid, gentamicinsulfat i natrijev deoksikolat).
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients and to residues (eggs and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)).
Potreban je oprez pri primjeni cjepiva u osoba s poznatom preosjetljivošću (osim anafilaktičke reakcije) na djelatnu tvar, neku od pomoćnih tvari i na ostatne tvari (jaja i pileće proteine, ovalbumin, kanamicin i neomicin sulfat, formaldehid i cetiltrimetilamonijev bromid (CTAB)).
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1 and to eggs, chicken proteins, kanamycin and neomycin sulphate, barium sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB).
Potreban je oprez pri primjeni cjepiva kod osoba s poznatom preosjetljivošću (osim anafilaktičke reakcije) na djelatnu tvar, na bilo koju pomoćnu tvar navedenu u dijelu 6.1 i na jaja, pileće bjelančevine, kanamicin i neomicin sulfat, barijev sulfat, formaldehid i cetiltrimetilamonij bromid (CTAB).
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1 and to residues (eggs and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, barium sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)).
Potreban je oprez pri primjeni cjepiva u osoba s poznatom preosjetljivošću (osim anafilaktičke reakcije) na djelatnu tvar, na bilo koju od pomoćnih tvari navedenih u dijelu 6.1 i na tvari u tragovima (jaja i pileće proteine, ovalbumin, kanamicin i neomicin sulfat, barijev sulfat, formaldehid i cetiltrimetilamonijev bromid (CTAB)).
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1, to thiomersal and to eggs, chicken proteins, kanamycin and neomycin sulphate, barium sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB).
Potreban je oprez pri primjeni cjepiva kod osoba s poznatom preosjetljivošću (osim anafilaktičke reakcije) na djelatnu tvar, na bilo koju pomoćnu tvar navedenu u dijelu 6.1, na tiomersal i na jaja, pileće bjelančevine, kanamicin i neomicin sulfat, barijev sulfat, formaldehid i cetiltrimetilamonij bromid (CTAB).
Caution is needed when Cubicin is given to patients with kidney problems and the medicine may need to be given less often.
Potreban je oprez kada se Cubicin daje bolesnicima s bubrežnim problemima, a lijek će možda biti potrebno davati rjeđe.
Caution is needed when Invirase is taken at the same time as some other medicines.
Potreban je oprez kada se lijek Invirase uzima istodobno s nekim drugim lijekovima.
Caution is recommended for patients with severe renal impairment or end-stage renal disease (see section 5.2).
Preporučuje se oprez kod bolesnika s teškim oštećenjem funkcije bubrega ili terminalnim stadijem bubrežne bolesti (vidjeti dio 5.2).
Caution is recommended in patients with previous history of pancreatitis.
Oprez je potreban u bolesnika s upalom gušterače u anamnezi.
Caution is recommended in patients with severely impaired hepatic function.
Oprez se preporučuje u bolesnika s teško oštećenom jetrenom funkcijom.
Caution is recommended in the case of co-administration.
Kod istodobne primjene potreban je oprez.
Caution is recommended in thyroidectomy patients receiving levothyroxine and imatinib.
Preporučuje se oprez u bolesnika kojima je učinjena tireoidektomija a primaju levotiroksin i imatinib.
Caution is recommended when administering Iclusig to patients with hepatic impairment (see sections 4.2 and 4.4).
Preporučuje se oprez prilikom primjene lijeka Iclusig u bolesnika s oštećenjem funkcije jetre (vidjeti dijelove 4.2 i 4.4)
Caution is recommended when administering Iclusig to patients with hepatic impairment (see sections 4.2 and 4.4).
Preporučuje se oprez prilikom primjene lijeka Iclusig u bolesnika s oštećenjem funkcije jetre (vidjeti dijelove 4.2 i 4.4).
Caution is recommended when administering Iclusig to patients with hepatic impairment (see sections 4.2 and 5.2).
Preporučuje se oprez prilikom primjene lijeka Iclusig u bolesnika s oštećenjem jetre (vidjeti dijelove 4.2 i 5.2).
Caution is recommended when administering Iclusig to patients with hepatic impairment (see sections 4.4 and 5.2).
Preporučuje se oprez prilikom primjene lijeka Iclusig u bolesnika s oštećenjem jetre (vidjeti dijelove 4.4 i 5.2).
Caution is recommended when co-administering fluticasone furoate with potent CYP3A4 inhibitors as an increase in systemic exposure cannot be ruled out.
Potreban je oprez prilikom istovremene primjene flutikazonfuroata s potentnim inhibitorima CYP3A4 s obzirom da se ne može isključiti povećanje sistemske izloženosti.
Caution is recommended when co-administering Senshio with fluconazole (see section 4.5).
Preporučuje se oprez pri istodobnoj primjeni lijeka Senshio i flukonazola (vidjeti dio 4.5).
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.4 and 5.2).
Preporučuje se oprez pri doziranju u bolesnika s teškim bubrežnim oštećenjem (klirens kreatinina < 30 ml/min) (vidjeti dijelove 4.4 i 5.2).